CORE LAB REPORTS THIRD QUARTER 2023 RESULTS
- REVENUE OF
$125.3 MILLION ; DOWN 2% SEQUENTIALLY; FLAT YEAR-OVER-YEAR - OPERATING INCOME OF
$14.7 MILLION ; EX-ITEMS,$16.0 MILLION , UP OVER 2% SEQUENTIALLY; UP 20% YEAR-OVER-YEAR - OPERATING MARGINS, EX-ITEMS, OF 13%
- GAAP EPS OF
$0.19 ; EX-ITEMS,$0.22 , UP 5% SEQUENTIALLY; UP 24% YEAR-OVER-YEAR - RESERVOIR DESCRIPTION OPERATING MARGINS, EX-ITEMS, OF 17%; INCREMENTAL MARGINS EXCEEDING 100% SEQUENTIALLY; EXCEEDING 90% YEAR-OVER-YEAR
- COMPANY ANNOUNCES STRATEGIC DIGITAL ROCK CHARACTERIZATION ALLIANCE WITH HALLIBURTON
- COMPANY ANNOUNCES Q4 2023 QUARTERLY DIVIDEND
Core's CEO,
Reservoir Description
Reservoir Description operations are closely correlated with trends in international and offshore activity levels, with approximately 80% of revenue sourced from projects originating outside the U.S. Revenue in the third quarter of 2023 was
During the third quarter of 2023, Core's
Also during the third quarter of 2023, Halliburton Company ("Halliburton") and Core Lab signed a strategic alliance in the
Production Enhancement
Production Enhancement operations, which are focused on complex completions in unconventional oil and gas reservoirs in the
During the third quarter of 2023, Core's Production Enhancement segment was engaged by a client in the
Also during the third quarter of 2023, Core's completion diagnostics were deployed in an innovative application for a client exploring for helium resources in the Four Corners' area of New Mexico. The project utilized Core's proprietary diagnostic technologies to assess well production and identify an optimum completion strategy. Core's Flow Profiler™ water-phase and gas-phase tracers were deployed into four stages of this vertical well, with unique tracers placed into each interval. Water and gas tracer concentrations in flowback samples were collected at the surface, allowing for delineation of the most promising helium-producing intervals. The operator also utilized Core's Completion Profiler® to better characterize the gas production from each interval. Through the use of Core's technologies, the operator identified the most promising stratigraphic target for future helium-producing wells planned for this area.
Liquidity, Free Cash Flow and Dividend
Core continues to focus on maximizing free cash flow ("FCF"), a non-GAAP financial measure defined as cash from operations less capital expenditures. For the third quarter of 2023, cash used in operations was approximately
- An additional
$14,000,000 of cash used to fund working capital requirements. Growth in inventory during the third quarter of 2023 was primarily caused by the lower-than-expected level of activity in theU.S. onshore market. TheU.S. onshore market is the largest market the Company serves with its product sales, and prolonged lead times associated with purchasing raw materials has resulted in the need to maintain higher levels of raw materials. Additionally, the Company continued to build stock to serve large international projects which are planned for delivery later in 2023 and 2024. The Company also carried approximately$5,000,000 less in accounts payable as ofSeptember 30, 2023 when compared toJune 30, 2023 . - Cash from operations for the third quarter of 2023 also includes
$11,300,000 in cash tax payments. Approximately$5,100,000 of these cash tax payments made during the third quarter of 2023 are expected to be recovered through a tax refund during the fourth quarter of 2023.
Core expects cash from operations to strengthen and the Company to generate positive free cash in future quarters. At the end of the third quarter of 2023, Core's net debt increased by
On
On
Return On Invested Capital
The Board and the Company's Executive Management continue to focus on strategies that maximize return on invested capital ("ROIC") and FCF, factors that have high correlation to total shareholder return. Core's commitment to an asset-light business model and disciplined capital stewardship promote capital efficiency and are designed to produce more predictable and superior long-term ROIC.
The Board has established an internal metric to demonstrate ROIC performance relative to the oilfield service companies listed as Core's Comp Group by Bloomberg, as the Company continues to believe superior ROIC will result in higher total shareholder return. Using Bloomberg's formula to reflect Core's financial performance in the third quarter of 2023, the Company's ROIC improved to 13.6%.
Industry and Core Lab Outlook and Guidance
Based on constant dialogue with the Company's global client base, Core Lab maintains its constructive outlook on international upstream activity for 2024 and beyond, as increasing levels of investment will be required to maintain and grow hydrocarbon production. The Company anticipates operator spending on long-cycle upstream projects in both onshore and offshore environments will continue to expand displaying an added level of sustainability for this upcycle. In the near-term, the global crude-oil market may remain volatile due to global recession fears, the extent and timing of
Core continues to anticipate a multi-year international recovery supported by increased spending on exploration in many regions across the globe and expanded development of existing fields to fortify crude-oil and natural gas reserves. This underlies Core's outlook for continued improvement in international onshore and offshore activity, with on-going projects around the globe, most notably across the
Core projects Reservoir Description's fourth quarter 2023 revenue to range from
The Company's fourth quarter 2023 revenue is projected to range from
The Company's fourth quarter 2023 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange. Fourth quarter 2023 guidance also assumes an effective tax rate of 20%.
Earnings Call Scheduled
The Company has scheduled a conference call to discuss Core's third quarter 2023 earnings announcement. The call will begin at
Core Laboratories Inc. is a leading provider of proprietary and patented reservoir description and production enhancement services and products used to optimize petroleum reservoir performance. The Company has over 70 offices in more than 50 countries and is located in every major oil-producing province in the world. This release, as well as other statements we make, includes forward-looking statements regarding the Company's future revenue, profitability, business strategies and developments, demand for the Company's products and services and for products and services of the oil and gas industry generally, made in reliance upon the safe harbor provisions of Federal securities law. The Company's outlook is subject to various important cautionary factors, including risks and uncertainties related to the oil and natural gas industry, business and general economic conditions, including inflationary pressures, the ability to achieve the benefits of the redomestication of the parent company from
The Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect events or circumstances that may arise after the date of this press release, except as required by law.
Visit the Company's website at www.corelab.com. Connect with Core Lab on Facebook, LinkedIn and YouTube.
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) (Unaudited) | ||||||||||||||||
Three Months Ended | % Variance | |||||||||||||||
|
|
| vs. Q2-23 | vs. Q3-22 | ||||||||||||
REVENUE | $ | 125,343 | $ | 127,881 | $ | 125,966 | (2.0) % | (0.5) % | ||||||||
OPERATING EXPENSES: | ||||||||||||||||
Costs of services and product sales | 96,617 | 100,295 | 98,930 | (3.7) % | (2.3) % | |||||||||||
General and administrative expense | 9,452 | 5,811 | 10,001 | 62.7 % | (5.5) % | |||||||||||
Depreciation and amortization | 3,929 | 3,937 | 4,171 | (0.2) % | (5.8) % | |||||||||||
Other (income) expense, net | 673 | (1,068) | (1,781) | NM | NM | |||||||||||
Total operating expenses | 110,671 | 108,975 | 111,321 | 1.6 % | (0.6) % | |||||||||||
OPERATING INCOME | 14,672 | 18,906 | 14,645 | (22.4) % | 0.2 % | |||||||||||
Interest expense | 3,147 | 3,236 | 3,138 | (2.8) % | 0.3 % | |||||||||||
Income before income taxes | 11,525 | 15,670 | 11,507 | (26.5) % | 0.2 % | |||||||||||
Income tax expense (benefit) | 2,305 | (7,259) | 3,856 | NM | (40.2) % | |||||||||||
Net income | 9,220 | 22,929 | 7,651 | (59.8) % | 20.5 % | |||||||||||
Net income (loss) attributable to non-controlling interest | (37) | 83 | 127 | NM | NM | |||||||||||
Net income attributable to Core Laboratories Inc. | $ | 9,257 | $ | 22,846 | $ | 7,524 | (59.5) % | 23.0 % | ||||||||
Diluted earnings per share | $ | 0.19 | $ | 0.48 | $ | 0.16 | (60.4) % | 18.8 % | ||||||||
Diluted earnings per share attributable to Core Laboratories Inc. | $ | 0.19 | $ | 0.48 | $ | 0.16 | (60.4) % | 18.8 % | ||||||||
Diluted weighted average common shares outstanding | 47,604 | 47,497 | 47,012 | 0.2 % | 1.3 % | |||||||||||
Effective tax rate | 20 | % | (46) | % | 34 | % | NM | NM | ||||||||
SEGMENT INFORMATION: | ||||||||||||||||
Revenue: | ||||||||||||||||
Reservoir Description | $ | 85,145 | $ | 83,384 | $ | 78,996 | 2.1 % | 7.8 % | ||||||||
Production Enhancement | 40,198 | 44,497 | 46,970 | (9.7) % | (14.4) % | |||||||||||
Consolidated | $ | 125,343 | $ | 127,881 | $ | 125,966 | (2.0) % | (0.5) % | ||||||||
Operating income: | ||||||||||||||||
Reservoir Description | $ | 12,992 | $ | 13,316 | $ | 9,798 | (2.4) % | 32.6 % | ||||||||
Production Enhancement | 1,544 | 5,498 | 4,417 | (71.9) % | (65.0) % | |||||||||||
Corporate and Other | 136 | 92 | 430 | NM | NM | |||||||||||
Consolidated | $ | 14,672 | $ | 18,906 | $ | 14,645 | (22.4) % | 0.2 % | ||||||||
"NM" means not meaningful | ||||||||||||||||
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) (Unaudited) | ||||||
Nine Months Ended | % Variance | |||||
2023 | 2022 | |||||
REVENUE | 5.4 % | |||||
OPERATING EXPENSES: | ||||||
Costs of services and product sales | 298,440 | 293,839 | 1.6 % | |||
General and administrative expense | 31,594 | 29,393 | 7.5 % | |||
Depreciation and amortization | 11,910 | 13,088 | (9.0) % | |||
Other (income) expense, net | (423) | (62) | NM | |||
Total operating expenses | 341,521 | 336,258 | 1.6 % | |||
OPERATING INCOME | 40,059 | 25,906 | 54.6 % | |||
Interest expense | 9,812 | 8,489 | 15.6 % | |||
Income before income taxes | 30,247 | 17,417 | 73.7 % | |||
Income tax expense (benefit) | (4,344) | 4,449 | NM | |||
Net income | 34,591 | 12,968 | 166.7 % | |||
Net income attributable to non-controlling interest | 115 | 266 | NM | |||
Net income attributable to Core Laboratories Inc. | 171.4 % | |||||
Diluted earnings per share | 160.7 % | |||||
Diluted earnings per share attributable to Core Laboratories Inc. | 170.4 % | |||||
Diluted weighted average common shares outstanding | 47,536 | 47,117 | 0.9 % | |||
Effective tax rate | (14) % | 26 % | NM | |||
SEGMENT INFORMATION: | ||||||
Revenue: | ||||||
Reservoir Description | 8.3 % | |||||
Production Enhancement | 132,863 | 132,597 | 0.2 % | |||
Total | 5.4 % | |||||
Operating income: | ||||||
Reservoir Description | 78.9 % | |||||
Production Enhancement | 10,324 | 8,447 | 22.2 % | |||
Corporate and Other | 955 | 1,374 | NM | |||
Total | 54.6 % | |||||
"NM" means not meaningful | ||||||
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited) | ||||||||||||||||
% Variance | ||||||||||||||||
ASSETS: |
|
|
| vs. Q2-23 | vs. Q4-22 | |||||||||||
Cash and cash equivalents | $ | 16,616 | $ | 26,204 | $ | 15,428 | (36.6) % | 7.7 % | ||||||||
Accounts receivable, net | 104,053 | 106,816 | 106,913 | (2.6) % | (2.7) % | |||||||||||
Inventories | 75,060 | 71,658 | 60,445 | 4.7 % | 24.2 % | |||||||||||
Other current assets | 32,815 | 31,446 | 28,916 | 4.4 % | 13.5 % | |||||||||||
Total current assets | 228,544 | 236,124 | 211,702 | (3.2) % | 8.0 % | |||||||||||
Property, plant and equipment, net | 99,499 | 101,662 | 105,028 | (2.1) % | (5.3) % | |||||||||||
Right of use assets | 53,101 | 55,456 | 52,379 | (4.2) % | 1.4 % | |||||||||||
Intangibles, goodwill and other long-term assets, net | 211,270 | 208,606 | 209,245 | 1.3 % | 1.0 % | |||||||||||
Total assets | $ | 592,414 | $ | 601,848 | $ | 578,354 | (1.6) % | 2.4 % | ||||||||
LIABILITIES AND EQUITY: | ||||||||||||||||
Accounts payable | $ | 34,097 | $ | 39,145 | $ | 45,847 | (12.9) % | (25.6) % | ||||||||
Short-term operating lease liabilities | 9,794 | 10,731 | 11,699 | (8.7) % | (16.3) % | |||||||||||
Other current liabilities | 40,359 | 46,318 | 45,589 | (12.9) % | (11.5) % | |||||||||||
Total current liabilities | 84,250 | 96,194 | 103,135 | (12.4) % | (18.3) % | |||||||||||
Long-term debt, net | 177,863 | 182,583 | 172,386 | (2.6) % | 3.2 % | |||||||||||
Long-term operating lease liabilities | 40,903 | 42,376 | 38,305 | (3.5) % | 6.8 % | |||||||||||
Other long-term liabilities | 59,948 | 61,091 | 75,574 | (1.9) % | (20.7) % | |||||||||||
Total equity | 229,450 | 219,604 | 188,954 | 4.5 % | 21.4 % | |||||||||||
Total liabilities and equity | $ | 592,414 | $ | 601,848 | $ | 578,354 | (1.6) % | 2.4 % | ||||||||
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) | ||||||||
Nine Months Ended | ||||||||
2023 | 2022 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
Net income | $ | 34,591 | $ | 12,968 | ||||
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||||||||
Stock-based compensation | 12,406 | 7,452 | ||||||
Depreciation and amortization | 11,910 | 13,088 | ||||||
Deferred income taxes | (14,757) | (1,807) | ||||||
Accounts receivable | 2,872 | (3,390) | ||||||
Inventories | (15,707) | (9,188) | ||||||
Accounts payable | (13,101) | 4,288 | ||||||
Other adjustments to net income | (12,854) | (11,666) | ||||||
Net cash provided by (used in) operating activities | 5,360 | 11,745 | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
Capital expenditures | (7,843) | (8,195) | ||||||
Net proceeds on life insurance policies and from insurance recovery | 3,375 | 2,642 | ||||||
Other investing activities | 262 | 639 | ||||||
Net cash provided by (used in) investing activities | (4,206) | (4,914) | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Repayment of long-term debt | (184,000) | (49,000) | ||||||
Proceeds from long-term debt | 190,000 | 44,000 | ||||||
Dividends paid | (1,401) | (1,389) | ||||||
Repurchase of common stock | (418) | (2,311) | ||||||
Equity related transaction costs | (2,842) | (411) | ||||||
Other financing activities | (1,305) | (1,691) | ||||||
Net cash provided by (used in) financing activities | 34 | (10,802) | ||||||
NET CHANGE IN CASH AND CASH EQUIVALENTS | 1,188 | (3,971) | ||||||
CASH AND CASH EQUIVALENTS, beginning of period | 15,428 | 17,703 | ||||||
CASH AND CASH EQUIVALENTS, end of period | $ | 16,616 | $ | 13,732 | ||||
Non-GAAP Information
Management believes that the exclusion of certain income and expenses enables it to evaluate more effectively the Company's operations period-over-period and to identify operating trends that could otherwise be masked by the excluded Items. For this reason, management uses certain non-GAAP measures that exclude these Items and believes that this presentation provides a clearer comparison with the results reported in prior periods. The non-GAAP financial measures should be considered in addition to, and not as a substitute for, the financial results prepared in accordance with GAAP, as more fully discussed in the Company's financial statements and filings with the Securities and Exchange Commission.
Reconciliation of Operating Income, Net Income and Diluted Earnings Per Share Attributable to Core Laboratories Inc. (In thousands, except per share data) (Unaudited) | ||||||||||||
Operating Income | ||||||||||||
Three Months Ended | ||||||||||||
|
|
| ||||||||||
GAAP reported | $ | 14,672 | $ | 18,906 | $ | 14,645 | ||||||
Stock compensation (1) | — | (934) | — | |||||||||
Loss on lease abandonment and assets write-down (2) | 633 | — | — | |||||||||
Gain on life insurance policies (3) | — | (1,965) | — | |||||||||
ATM termination costs (4) | 455 | — | — | |||||||||
Foreign exchange losses (gains) | 238 | (386) | (1,303) | |||||||||
Excluding specific items | $ | 15,998 | $ | 15,621 | $ | 13,342 | ||||||
Net Income Attributable to Core Laboratories Inc. | ||||||||||||
Three Months Ended | ||||||||||||
|
|
| ||||||||||
GAAP reported | $ | 9,257 | $ | 22,846 | $ | 7,524 | ||||||
Stock compensation (1) | — | (747) | — | |||||||||
Loss on lease abandonment and assets write-down (2) | 505 | — | — | |||||||||
Gain on life insurance policies (3) | — | (1,572) | — | |||||||||
ATM termination costs (4) | 364 | — | — | |||||||||
Foreign exchange losses (gains) | 190 | (309) | (1,043) | |||||||||
Debt issuance costs write off (5) | — | — | 171 | |||||||||
Reversal of net deferred tax liabilities and effect of higher (lower) tax rate (6) | — | (10,394) | 1,553 | |||||||||
Excluding specific items | $ | 10,316 | $ | 9,824 | $ | 8,205 | ||||||
Diluted Earnings Per Share Attributable to Core Laboratories Inc. | ||||||||||||
Three Months Ended | ||||||||||||
|
|
| ||||||||||
GAAP reported | $ | 0.19 | $ | 0.48 | $ | 0.16 | ||||||
Stock compensation (1) | — | (0.02) | — | |||||||||
Loss on lease abandonment and assets write-down (2) | 0.01 | — | — | |||||||||
Gain on life insurance policies (3) | — | (0.03) | — | |||||||||
ATM termination costs (4) | 0.01 | — | — | |||||||||
Foreign exchange losses (gains) | 0.01 | — | (0.01) | |||||||||
Reversal of net deferred tax liabilities and effect of higher (lower) tax rate (5) | — | (0.22) | 0.03 | |||||||||
Excluding specific items | $ | 0.22 | $ | 0.21 | $ | 0.18 | ||||||
(1) Three months ended | ||||||||||||
(2) Three months ended | ||||||||||||
(3) Three months ended | ||||||||||||
(4) Three months ended | ||||||||||||
(5) Three months ended | ||||||||||||
Segment Information (In thousands) (Unaudited) | ||||||||||||
Operating Income | ||||||||||||
Three Months Ended | ||||||||||||
Reservoir Description | Production Enhancement | Corporate and Other | ||||||||||
GAAP reported | $ | 12,992 | $ | 1,544 | $ | 136 | ||||||
Loss on lease abandonment and assets write-down (1) | 633 | — | — | |||||||||
ATM termination costs (2) | 292 | 163 | — | |||||||||
Foreign exchange losses (gains) | 162 | (65) | 141 | |||||||||
Excluding specific items | $ | 14,079 | $ | 1,642 | $ | 277 | ||||||
(1) Includes the write-down of right of use assets and leasehold improvements and other exit costs associated with consolidation of certain facilities. | ||||||||||||
(2) Includes the write off of previously deferred costs upon termination of our ATM Program. | ||||||||||||
Return on Invested Capital
Return on Invested Capital ("ROIC") is presented based on management's belief that this non-GAAP measure is useful information to investors and management when comparing profitability and the efficiency with which capital has been employed over time relative to other companies. The Board has established an internal metric to demonstrate ROIC performance relative to the oilfield service companies listed as Core's Comp Group by Bloomberg. ROIC is not a measure of financial performance under GAAP and should not be considered as an alternative to net income.
ROIC of 13.6% is defined by Bloomberg as Net Operating Profit After Tax ("NOPAT") of
Free Cash Flow
Core uses the non-GAAP financial measure of free cash flow to evaluate its cash flows and results of operations. Free cash flow is an important measurement because it represents the cash from operations, in excess of capital expenditures, available to operate the business and fund non-discretionary obligations. Free cash flow is not a measure of operating performance under GAAP and should not be considered in isolation nor construed as an alternative consideration to operating income, net income, or cash flows from operating, investing, or financing activities, each as determined in accordance with GAAP. Free cash flow should not be considered a measure of liquidity. Moreover, since free cash flow is not a measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented may not be comparable to similarly titled measures presented by other companies.
Computation of Free Cash Flow (In thousands) (Unaudited) | |||||||||
Three Months Ended | Nine Months Ended | ||||||||
Net cash provided by (used in) operating activities | $ | (212) | $ | 5,360 | |||||
Capital expenditures | (3,461) | (7,843) | |||||||
Free cash flow | $ | (3,673) | $ | (2,483) | |||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/core-lab-reports-third-quarter-2023-results-301974793.html
SOURCE Core Laboratories Inc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SpaceX: New Street Research sees 22% upside from proposed IPO price
- InventHelp Inventors Develop Handsfree Umbrella (RKH-1001)
- Transformational Coach and Bestselling Author Lainie Etzioni Launches The Unbecoming Method to Help Women Finally Change It
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Dividend, Crude Oil, Earnings, Definitive Agreement, Equity OfferingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share